American depositary receipts (ADRs) of Novartis (NVS) gained Monday as new research showed the company's brea༒st cancer treatment, Kisqali, producedܫ longer success than originally thought.

The company reported an updated analysis of a Phase 3 澳洲幸运5官方开奖结果体彩网:clinical trial of Kisqali combined with endocrine therapy (ET) found "a deepening benefit beyond the three-year treatment period, reducing the risk of recurrence by 28.5%" for those with stage II or III HR+/HER2- early breast cancer compared to ET alone.  

Trial investigator Dr. Peter Fasching noted that patients diagnosed with that form of breast cancer face "substantial risk of cancer coming back as metastatic disease," and that clinicians have been looking for ways to address it. Dr. Fasching added that the results were important because the study included a broad range of those at risk of recurrence who need new treatment options to reduce that risk.

Novartis Expects FDA Decision This Quarter

Novartis explained that it submitted the results to the 澳洲幸运5官方开奖结果体彩网:Food and Drug Administration (FDA) and 澳洲幸运5官方开奖结果体彩网:European Medicines Agency (EMA) last year, and expects FDA regulatory action on approval for the treatment𝓀 this quarter. 

Novartis ADRs, which were up about 1% to $116.61 soon after the opening bell Monday, hit an all-time high late last month, and although they've lost some ground, they're still up 15% this year.